Coagulation factors II, V, VII, VIII, IX and X are produced by hepatocytes.So factors VIII and IX deficiencies, which result in hemophilia A and B, have the potential torespond to cellular replacement therapy. Embryonic stem (ES) cells provide a unique source fortherapeutic applications. Here, E14 mouse ES cells have been induced into hepatocytes in vitro.Morphology revealed that ES-derived hepatic-like cells were round or polyhedral shaped with distinctboundary of individual cells, and some arranged in trabeculae. These cells expressed endodermal- orliver-specific mRNA---transthyretin (TTR), alpha 1-anti-trypsin (AAT), alpha-fetoprotein (AFP),albumin (ALB), glucose-6-phoshpatase (G6P) and tyrosine aminotransferase (TAT). Approximately(85.1±0.5)% of the ES-derived cells was stained positive green with ICG uptake. These cells werealso stained magenta as a result of PAS reaction. In this paper, expression of coagulation factorsVIII and IX mRNA in the ES-derived cells is documented. Therefore, ES cells might be developed assubstitute donor cells for the therapy of coagulation factor deficiencies.
